EBAY Form 144 Notice — 4,439 Common Shares via Morgan Stanley ($399,332)
Rhea-AI Filing Summary
Form 144 notice for EBAY Inc. This filing reports a proposed sale of 4,439 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $399,332.44 and an approximate sale date of 09/18/2025. The filing lists total shares outstanding as 457,000,000.
The shares were acquired as Restricted Stock Units from the issuer on 09/15/2025 and payment/settlement is recorded on the same date. No other securities were reported sold in the past three months. The filer certifies they are not aware of undisclosed material adverse information about the issuer.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine insider sale notice disclosing a small block of RSU-derived shares for sale, no past 3-month sales reported.
The filing documents a proposed sale of 4,439 common shares by a person associated with EBAY, routed through Morgan Stanley Smith Barney LLC, with an estimated market value of $399,332.44 and an intended trade date of 09/18/2025. The securities were acquired as Restricted Stock Units on 09/15/2025. Given the reported shares outstanding of 457,000,000, the block represents a de minimis percentage of the company’s equity. The filer also affirms the absence of undisclosed material adverse information. This is a routine disclosure required under Rule 144 and provides transparency on insider liquidity.
TL;DR: Compliance-focused filing showing an insider following Rule 144 mechanics and reaffirming public-disclosure status.
The form supplies the issuer, broker, share count, acquisition method (RSUs), acquisition date, and intended sale date. The declaration that the seller does not possess undisclosed material information and the inclusion of broker and transaction details align with standard governance and securities-compliance practices. No related-party aggregation or recent sales were reported, and no trading-plan date under Rule 10b5-1 is indicated. The document appears procedural and consistent with fiduciary disclosure obligations.